Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 4, Issue 1, Pages 38-49Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-013-0160-0
Keywords
Drug delivery systems; Cancer therapeutics; Combination therapy; RNAi
Funding
- Association for International Cancer Research (AICR)
- German-Israel Foundation (GIF)
- Marguerite Stolz Research Fund for outstanding faculty
- MAGNET Program of the Office of the Chief Scientist of the Israel Ministry of Industry, Trade Labor
- ISRAEL SCIENCE FOUNDATION [1309/10]
- US-Israel Binational Science Foundation [2007347]
- Swiss Bridge Award
- Israeli National Nanotechnology Initiative (INNI)
- Focal Technology Area (FTA) program: Nanomedicine for Personalized Theranostics
- Leona M. and Harry B. Helmsley Nanotechnology Research Fund
- Rimonim Consortium
Ask authors/readers for more resources
MicroRNAs (miRNAs) are small noncoding RNAs found to govern nearly every biological process. They frequently acquire a gain or a loss of function in cancer, hence playing a causative role in the development and progression of cancer. There are major obstacles on the way for the successful delivery of miRNA, which include low cellular uptake of the RNA and endosomal escape, immunogenicity, degradation in the bloodstream, and rapid renal clearance. The delivered miRNA needs to be successfully routed to the target organ, enter the cell and reach its intracellular target in an active form. Consequently, in order to exploit the promise of RNA interference, there is an urgent need for efficient methods to deliver miRNAs. These can be divided into three main categories: complexation, encapsulation, and conjugation. In this review, we will discuss the special considerations for miRNA delivery for cancer therapy, focusing on nonviral delivery systems: lipid, polymeric, and inorganic nanocarriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available